Mesirov’s appointment is a testament to her enduring commitment to advancing computational science, particularly the use of high-dimensional data analytics and artificial intelligence in oncology. Her role will encompass devising overarching computational strategies in tandem with the institute’s leadership and synergizing projects across multiple specialized centers. This integrated approach aims to catalyze breakthroughs in cancer therapeutics through the rapid deployment of innovative AI tools that enhance data interpretation and translational research.

Throughout her prolific career, Mesirov has been recognized for her groundbreaking contributions to the development of computational platforms that democratize access to complex genomic data analysis. Notably, platforms such as GenePattern, the widely employed Gene Set Enrichment Analysis (GSEA) coupled with the Molecular Signature Database (MSigDB), and the Integrative Genomics Viewer (IGV) exemplify her vision for enabling researchers worldwide to interrogate vast genomic datasets without necessitating advanced bioinformatics training. These tools have become foundational assets in cancer biology research, adopted by over a million users globally across more than 100 countries.

The landscape of computational oncology has evolved substantially in recent decades, with Mesirov at the forefront of melding machine learning methodologies with functional molecular data derived from patient tumors. This fusion enables the identification of biological mechanisms underlying diverse tumor subtypes, moving oncology toward a personalized medicine paradigm. Her research endeavors meticulously dissect cancer heterogeneity, aiming to inform treatment selection by identifying candidate therapeutics that optimize efficacy while minimizing relapse risk.

Prior to her transition to Sanford Burnham Prebys, Mesirov enriched the University of California San Diego’s academic and clinical bioinformatics framework as Associate Vice Chancellor for Computational Health Sciences. Her concurrent leadership at the Structural and Functional Genomics Program within the Moores Cancer Center fostered translational strategies grounded in high-throughput structural genomic data. Additionally, her multidisciplinary collaborations have bridged computational biology with pediatric oncology, supporting precision genome-based therapies for childhood brain and spinal tumors at Rady Children’s Hospital.

Mesirov’s grounding in mathematics, with foundational degrees from the University of Pennsylvania and Brandeis University, catalyzed her expertise in algorithm development, cryptology, and high-performance computing. Early roles at institutions including the Broad Institute, where she ascended to Associate Director and Chief Informatics Officer, positioned her to influence the nascent field of genomics informatics profoundly. Her tenure at the Broad Institute was marked by a focus on designing efficacious computational infrastructures enabling large-scale genomic data integration.

Her commitment to nurturing the next generation of computational scientists is a hallmark of her current vision. She underscores the importance of mentoring by emphasizing how emergent generative AI tools can be harnessed scientifically, enhancing both research capability and educational development. By embedding these advanced computational paradigms within institutional frameworks, Mesirov aims to create a fertile environment for innovation that will yield novel therapeutic routes for cancer.

The impact of Mesirov’s collective work also reflects broad engagement with professional communities. As a former president of the Association for Women in Mathematics and a fellow of several prestigious organizations including the American Association for the Advancement of Science and the International Society for Computational Biology, she has championed diversity and excellence in STEM disciplines. Her extensive publication record, spanning over 300 peer-reviewed articles and technical reports, attests to her sustained scholarly influence.

At Sanford Burnham Prebys, her strategic role involves not only overseeing computational science but also integrating AI-driven analytics into the broader biomedical research enterprise. This integration is anticipated to enhance predictive modeling of tumor behavior, drug response, and patient outcomes, which are critical for designing next-generation personalized treatments. Such innovation carries the promise of redefining therapeutic paradigms and improving survival rates across cancer subtypes.

Mesirov’s personal engagement with cancer research is deeply rooted in both academic passion and personal experience. She has articulated a sustained fascination with cancer’s biological complexity and an unwavering drive to translate computational discoveries into tangible clinical benefits. By bridging mathematical rigor and biological insight, her work continues to illuminate the path toward understanding cancer’s molecular underpinnings and tailoring interventions accordingly.

Her trajectory prior to her current and recently assumed roles includes pivotal contributions in the private sector and academia, encompassing positions at Thinking Machines Corporation and the Institute for Defense Analyses. These experiences enriched her expertise in cryptology, algorithm design, and computational efficiency, skills that she adeptly translated into the biological domain. Such a multidisciplinary foundation underscores the innovative cross-pollination that characterizes her approach to computational science.

In summary, Jill P. Mesirov’s integration into Sanford Burnham Prebys embodies a strategic enhancement in the application of computational biology and AI-driven methods to cancer research. By focusing on accessible and powerful tools that facilitate genomic data analysis and personalized therapy prediction, Mesirov is poised to catalyze significant advancements in the quest to understand and treat cancer more effectively. Her leadership exemplifies the convergence of mathematics, computer science, and medicine, heralding a new era in translational research and precision oncology.

Subject of Research: Computational biology and artificial intelligence applications in cancer research and personalized medicine.

Article Title: Jill P. Mesirov Joins Sanford Burnham Prebys to Pioneer AI-Driven Cancer Research

News Publication Date: Not specified; announcement effective July 1, 2026.

Web References:

• Sanford Burnham Prebys Medical Discovery Institute: https://sbpdiscovery.org/research/
• Integrative Genomics Viewer (IGV): https://igv.org
• Gene Set Enrichment Analysis (GSEA) and Molecular Signature Database (MSigDB): https://www.gsea-msigdb.org

Image Credits: Jill Mesirov, ©Jill Mesirov

Keywords: Computational biology, Bioinformatics, Cancer research, Artificial intelligence, Machine learning, Genomics, Personalized medicine, Translational research, Cancer therapeutics, High-performance computing, Genomic data analysis, Computational science

Dr. Boutros will also assume roles as senior vice president of data sciences and professor, continuing his distinguished career trajectory that melds computational biology with clinical insights. Before this appointment, he was a professor at UCLA’s David Geffen School of Medicine, with joint appointments in human genetics and urology, and served as interim vice dean for research. His research prowess lies in harnessing artificial intelligence (AI), machine learning (ML), and the computational sciences to decode voluminous, complex datasets inherent in modern oncological studies, which are crucial for designing innovative and predictive cancer research projects.

At the core of Boutros’ scientific inquiry is the integration of diverse datasets — clinical, molecular, and imaging — to personalize cancer therapies. His commitment to identifying precise biomarkers epitomizes a critical shift in oncology: moving beyond one-size-fits-all treatments to precision medicine strategies that maximize therapeutic benefit while minimizing adverse effects. According to Sanford Burnham Prebys CEO David A. Brenner, Dr. Boutros exemplifies pioneering “over-the-horizon thinking,” using rapidly evolving computational methods to tackle previously insurmountable questions in cancer biology and treatment.

Paul Boutros’ academic background underpins his groundbreaking approach. He earned his Bachelor of Science in Chemistry from the University of Waterloo in 2004, followed by a PhD in Medical Biophysics from the University of Toronto in 2008, where he additionally completed an executive MBA. His early research career began at the Ontario Institute for Cancer Research, where he progressed from fellow to principal investigator. Throughout his career, Boutros has published over 200 peer-reviewed articles and received numerous accolades, including the Dorval Prize by the Canadian Cancer Society, recognizing the top early career investigator nationwide.

The Sanford Burnham Prebys Cancer Center’s mission reflects a focus on fundamental cancer biology and translational studies that drive novel clinical applications. Faculty expertise spans multiple disciplines, including cell biology, immunology, epigenetics, metabolism, aging, and computational science. Collaborations with the Center for Therapeutics Discovery and the Center for Data Science and Artificial Intelligence further augment the center’s capabilities, promoting innovation at the intersection of biological research and computational analysis.

A recent notable example of Boutros’ innovative research leverages AI and computational tools to investigate the interplay between exercise and prostate cancer progression. Prostate cancer remains the second leading cause of cancer deaths among American men, and despite its prevalence, the role of lifestyle interventions like exercise in altering disease trajectory has been poorly quantified under controlled conditions. In a 2024 study published in JAMA Oncology, Boutros and colleagues carried out a decentralized, Phase I controlled trial examining how prescribed treadmill walking impacts biomarkers linked to prostate cancer outcomes.

The trial enrolled 53 previously inactive men aged 47 to 74 with diagnosed prostate cancer, equipping participants nationwide with a home treadmill, smartwatch, iPad, and other health monitoring devices. This infrastructure allowed real-time remote supervision of exercise regimens ranging from 90 to 450 minutes per week. The dual biomarkers assessed were Ki-67, a proliferative index marking the rate of cancer cell division, and prostate-specific antigen (PSA), an established marker for prostate cancer risk and progression. Their methodological rigor ensured quantifiable evaluation of exercise dose and corresponding biological impact.

Findings from this pioneering trial revealed that high levels of exercise were safely tolerated and that exercising approximately 225 minutes weekly emerged as the optimal “dose” for mitigating prostate cancer risk, as evidenced by favorable changes in Ki-67 and PSA biomarkers. Lesser durations yielded no significant biomarker change, while more extensive exercise produced only marginally increased benefits. This outcome signals a potential paradigm shift in prostate cancer management, suggesting that precisely prescribed exercise could function as an adjunct therapy, modifiable through computational precision.

Building upon this work, Boutros’ team has initiated a multi-institutional Phase 2 clinical trial, now listed on ClinicalTrials.gov, to compare the progression of prostate cancer in men performing targeted exercise regimens to those following typical activity levels. The integration of wearable technology, real-time data analytics, and personalized exercise prescriptions exemplifies how computational medicine can redefine treatment approaches. This strategy juxtaposes traditional pharmaceutical interventions with novel lifestyle-modification therapies under data-driven oversight.

In sum, Paul Boutros embodies the transformative power of computational biology and data science in oncology. His leadership at Sanford Burnham Prebys is poised to accelerate fundamental discoveries and translation into clinical innovation. By bridging artificial intelligence, big data, and patient-centered trials, Boutros is setting a new standard for combating complex diseases like cancer through integrative, technology-empowered research paradigms. As the landscape of cancer research evolves, computationally driven insights such as these are critical to developing precision oncology that improves outcomes for millions globally.

Subject of Research: Computational Biology and Cancer Research, Exercise Therapy in Prostate Cancer
Article Title: Paul Boutros Appointed Director of Sanford Burnham Prebys Cancer Center, Pioneers Computational Oncology and Exercise Therapy Research
News Publication Date: 2024
Web References:
– National Cancer Institute Cancer Centers: https://www.cancer.gov/research/infrastructure/cancer-centers
– JAMA Oncology Exercise Trial Article: https://jamanetwork.com/journals/jamaoncology/fullarticle/2821207
– Sanford Burnham Prebys Centers:
– Center for Therapeutics Discovery: https://sbpdiscovery.org/research/centers/center-for-therapeutics-discovery/
– Center for Data Science and Artificial Intelligence: https://sbpdiscovery.org/research/centers/center-for-data-science/
– Clinical Trial Registration: https://www.clinicaltrials.gov/study/NCT05751434
Image Credits: Sanford Burnham Prebys
Keywords: Cancer, Prostate cancer, Physical exercise, Computational biology, Informatics, Computer science, Machine learning, Artificial intelligence

Synovial sarcoma’s hallmark is a unique chromosomal translocation that fuses two genes, SS18 and SSX, generating the SS18::SSX fusion oncoprotein. This aberrant protein acts as a molecular driver of cancer, orchestrating epigenetic and transcriptional reprogramming that sustains the malignant identity and proliferative capacity of these cells. The exact mechanisms through which the fusion oncoprotein hijacks cellular processes have remained elusive, complicating efforts to develop targeted therapies.

Recently, a multidisciplinary group of researchers from Sanford Burnham Prebys Medical Discovery Institute, alongside collaborators at UCLA, UC San Diego, and the University of Edinburgh, published groundbreaking findings that illuminate a novel vulnerability in synovial sarcoma’s molecular armor. By integrating publicly available genomic datasets with their own experimental screenings in cell-based and animal models, this team identified the SUMO2 gene as a critical dependency selectively essential for synovial sarcoma cell growth.

SUMO2 encodes a small ubiquitin-like modifier protein that participates in post-translational modifications known as SUMOylation. This cellular process modulates protein function, localization, and interactions, thereby influencing epigenetic landscapes and gene expression patterns. Their data suggest that SS18::SSX fusion oncoprotein activates SUMO2, facilitating the cancer cells’ aberrant epigenetic programs and promoting sarcomagenesis.

To explore the therapeutic potential of targeting SUMO2, the researchers employed TAK-981, a small molecule inhibitor that impedes the SUMOylation pathway by blocking SUMO2 conjugation. Treatment with TAK-981 significantly impaired synovial sarcoma cell viability in vitro, accompanied by downregulation of gene networks under the control of the SS18::SSX fusion oncoprotein. The inhibitor not only disrupted the proliferation of cancerous cells but also lowered cellular levels of the fusion oncoprotein itself, underscoring a feedback mechanism that may enhance treatment efficacy.

Complementing cellular studies, in vivo experiments in mouse models demonstrated that SUMO2 inhibition curtailed tumor growth, reinforcing the notion that targeting this pathway can effectively attenuate sarcomagenesis. These findings also imply that TAK-981 might sensitize synovial sarcoma cells to standard chemotherapeutic regimens, suggesting a combinatorial strategy could yield synergistic effects in the clinical setting.

The significance of these results lies in bridging the gap between genomic data and actionable therapeutic interventions. By leveraging public cancer dependency maps and validating hits in biologically relevant models, the investigators exemplify the power of precision medicine approaches in uncovering cancer-specific vulnerabilities. Their work exemplifies how data-driven methodologies guide innovative drug discovery, particularly for rare cancers lacking effective targeted therapies.

Despite advancements, synovial sarcoma remains a formidable disease with roughly a 50-60% five-year survival rate for patients with metastatic progression. The ability of this malignancy to metastasize predominantly to the lungs, combined with the absence of tailored treatments, underscores the urgent need for new modalities. The discovery of SUMO2’s central role offers promise not only as a monotherapy target but as a gateway to understanding cancer epigenetics in fusion-driven sarcomas.

According to Dr. Rema Iyer, lead author and recent graduate from Sanford Burnham Prebys Graduate School of Biomedical Sciences, the complexity of synovial sarcoma’s epigenetic rewiring has hindered targeted drug development. The study’s insights into SUMO2 highlight a viable node for therapeutic intervention that had previously escaped attention because of the intricate interplay of oncoproteins and cellular epigenomic states.

Senior author Dr. Ani Deshpande, professor at Sanford Burnham Prebys and leader of the Cancer Genome and Epigenetics Program, emphasizes that SUMO2 inhibitors like TAK-981 carry strong potential for clinical translation. Given prior evidence of TAK-981’s efficacy in preclinical models of acute myeloid leukemia and pancreatic cancer, these findings strengthen the rationale for advancing this inhibitor into clinical trials for synovial sarcoma patients.

The methodology underpinning this research involved rigorous comparative screening across various platforms: analyses of DepMap’s expansive genomic datasets, cell culture model systems, and live animal experiments. This multi-layered approach allowed for a robust identification of genes essential to synovial sarcoma growth, out of which SUMO2 emerged as a consistent and druggable target.

While the immediate therapeutic implications center on SUMO2 inhibition, the broader impact resides in the conceptual framework that fusion oncoproteins like SS18::SSX impose epigenetic dependencies exploitable by precision drugs. Researchers worldwide now may consider SUMOylation pathways as fertile ground in the fight against other fusion-driven sarcomas and potentially beyond.

This study marks a critical advance in synovial sarcoma research, paving the way for targeted, mechanism-based therapies. It is a testament to the synergy between cutting-edge genomic technology and translational science, promising a future where even the rarest and most aggressive cancers can be tackled with tailored, effective interventions.

—

Subject of Research: Animals

Article Title: Targeting SUMO2 reverses aberrant epigenetic rewiring driven by SS18::SSX fusion oncoproteins and impairs sarcomagenesis

News Publication Date: 13-Aug-2025

Web References:

• The EMBO Journal article
• DepMap Consortium

References: DOI 10.1038/s44318-025-00526-w

Keywords: Cancer, Metastasis, Sarcoma, Oncoproteins